NCT06538558View on ClinicalTrials.gov

Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

October 14, 2025

Study Completion Date

November 30, 2025

Conditions
Opioid Use Disorder
Interventions
DRUG

Tezampanel

Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation

DRUG

Placebo

Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.

Trial Locations (1)

46202

RECRUITING

Indiana University School of Medicine, Indianapolis

All Listed Sponsors
collaborator

Indiana University School of Medicine

OTHER

lead

Proniras Corporation

INDUSTRY